Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 7/20 | 0.50 |
| ▸ | CES1 | P23141 | 7/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16044031 | 0.87 | DGAT1 (0.37) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL28915628 | 0.86 | CES2 (0.46) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL1088812 | 0.86 | CES1 (0.54) | CES2CES1ALDH1A1CA1FAAH | |
| SCHEMBL9431005 | 0.85 | CES2 (0.56) | CES2CES1ALDH1A1TSHRFAAH | |
| SCHEMBL28694822 | 0.83 | HDAC6 (0.36) | CES2CES1HDAC1HDAC2CA1 | |
| SCHEMBL1088865 | 0.83 | CES2 (0.58) | CES2CES1ALDH1A1TSHRFAAH | |
| SCHEMBL28241366 | 0.83 | CES2 (0.58) | CES2CES1ALDH1A1TSHRFAAH | |
| SCHEMBL28191479 | 0.83 | CES2 (0.58) | CES2CES1ALDH1A1TSHRFAAH | |
| SCHEMBL12216208 | 0.81 | TDP1 (0.38) | HDAC1HDAC2DGAT1HDAC6 | |
| SCHEMBL1088039 | 0.80 | CA1 (0.37) | FFAR3ALDH1A1CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396477-A | Pyridyl-substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-112601751-A | Fused thiophene compounds | 拜欧斯瑞克斯公司 | 2021-04-02 | — | — | CN | disclosed |
| US-9266853-B2 | Orally available viridiofungin derivative possessing anti-HCV activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266853-B2 | Orally available viridiofungin derivative possessing anti-HCV activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266853-B2 | Orally available viridiofungin derivative possessing anti-HCV activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2886530-A1 | ORALLY ADMINISTRABLE VIRIDIOFUNGIN DERIVATIVE HAVING ANTI-HCV ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-06-24 | — | — | EP | disclosed |
| EP-2886530-A1 | ORALLY ADMINISTRABLE VIRIDIOFUNGIN DERIVATIVE HAVING ANTI-HCV ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014027696-A1 | ORALLY ADMINISTRABLE VIRIDIOFUNGIN DERIVATIVE HAVING ANTI-HCV ACTIVITY | 中外製薬株式会社 (JP) | 2014-02-20 | — | — | WO | disclosed |
| CN-1159289-C | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases | ������˹ҩƷ��˾ | 2004-07-28 | — | — | CN | disclosed |
| EP-0544819-B1 | INDOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5459150-A | Treatment of allergies and inflammatory diseases | ABBOTT LABORATORIES (US) | 1995-10-17 | — | — | US | disclosed |
| EP-0544819-A4 | INDOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS | — | 1993-10-20 | — | — | EP | disclosed |
| EP-0544819-A1 | INDOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS. | ABBOTT LAB (US) | 1993-06-09 | — | — | EP | disclosed |
| US-5095031-A | Enzyme inhibitors, antiallergens, antiinflammatory | ABBOTT LABORATORIES (US) | 1992-03-10 | — | — | US | disclosed |
| WO-1992003132-A1 | INDOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | ZC3HAV1, SLC10A1, CYP51A1 | CES2 614/4885CES1 44/4885HDAC3 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.